Dopamine

Dopamine

SCHEMBL4918133

NCCc1ccc(O)c(O)c1.O=P(O)(O)O

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1

The experimentally established mechanism targets of Dopamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.81
MAPT P10636 3/20 0.81
MAPK1 P28482 3/20 0.81
TAAR1 Q96RJ0 3/20 0.81
ADRA2A P08913 2/20 0.81
DRD2 P14416 2/20 0.81
DRD1 P21728 2/20 0.81
DRD4 P21917 2/20 0.81
DRD5 P21918 2/20 0.81
SLC6A2 P23975 2/20 0.81
DRD3 P35462 2/20 0.81
RECQL P46063 2/20 0.81
SLC6A3 Q01959 2/20 0.81
TDP1 Q9NUW8 2/20 0.81
ALOX15 P16050 2/20 0.81
ALDH1A1 P00352 2/20 0.81
APEX1 P27695 2/20 0.81
TP53 P04637 1/20 0.81
ADRB2 P07550 1/20 0.81
HTR1A P08908 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dopamine SCHEMBL28531201 1.00 KDM4E (0.81) KDM4EMAPTMAPK1TAAR1ADRA2A
Dopamine SCHEMBL30379944 0.90 KDM4E (1.00) KDM4EMAPTMAPK1TAAR1ADRA2A
Dopamine SCHEMBL496657 0.90 KDM4E (1.00) KDM4EMAPTMAPK1TAAR1ADRA2A
Dopamine SCHEMBL16685137 0.90 KDM4E (1.00) KDM4EMAPTMAPK1TAAR1ADRA2A
Dopamine SCHEMBL29375089 0.90 KDM4E (1.00) KDM4EMAPTMAPK1TAAR1ADRA2A
Dopamine SCHEMBL9166387 0.90 KDM4E (1.00) KDM4EMAPTMAPK1TAAR1ADRA2A
Dopamine SCHEMBL29362033 0.90 KDM4E (1.00) KDM4EMAPTMAPK1TAAR1ADRA2A
Dopamine SCHEMBL18159501 0.90 KDM4E (1.00) KDM4EMAPTMAPK1TAAR1ADRA2A
Dopamine SCHEMBL8505 0.90 KDM4E (1.00) KDM4EMAPTMAPK1TAAR1ADRA2A
Dopamine SCHEMBL23704750 0.88 KDM4E (1.00) KDM4EMAPTMAPK1TAAR1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119881040-A Photoelectrochemical sensor of Z-type nano heterojunction, and preparation method and application thereof 安徽工程大学 2025-04-25 CN claimed
CN-114392245-B Dopamine-embedded nano-selenium assembled compound and preparation method thereof 自然资源部第三海洋研究所 2023-10-10 CN claimed
CN-114392236-B Co-doped dopamine-nano elemental selenium composition and preparation method thereof 自然资源部第三海洋研究所 2023-06-27 CN claimed
US-20220416230-A1 ELECTRODE MATERIALS, AND METHODS OF MANUFACTURING AND USE THEREOF JINAN UNIVERSITY (CN) 2022-12-29 US claimed
CN-114392245-A Dopamine-embedded nano-selenium assembly compound and preparation method thereof 自然资源部第三海洋研究所 2022-04-26 CN claimed
CN-114392236-A Co-doped dopamine-nano elemental selenium composition and preparation method thereof 自然资源部第三海洋研究所 2022-04-26 CN claimed
CN-114291965-A System for ecological innocent treatment of domestic sewage 内江师范学院 2022-04-08 CN claimed
CN-110987833-A Glucose biosensor material, preparation method and application 河北农业大学 2020-04-10 CN claimed
CN-105136888-B A kind of glucose oxidase electrode based on Graphene derivative and preparation method thereof 南京理工大学 2018-05-01 CN claimed
CN-106018533-A Molecularly imprinted electrochemical sensor for detecting trace sulfamonomethoxine 肇庆学院 2016-10-12 CN claimed
CN-105136888-A Graphene derivative based glucose oxidase electrode and preparation method thereof UNIV NANJING SCIENCE & TECH 2015-12-09 CN claimed
CN-103272499-A Dopamine-polyethersulfone composite membrane and preparation method thereof UNIV TIANJIN 2013-09-04 CN claimed
US-20260091004-A1 PHARMACEUTICAL INJECTABLE SOLUTION COMPRISING DOPAMINE INBRAIN PHARMA (FR) 2026-04-02 US disclosed
US-12482814-B2 Electrode materials, and methods of manufacturing and use thereof JINAN UNIVERSITY (CN) 2025-11-25 US disclosed
EP-4586995-A1 PHARMACEUTICAL INJECTABLE SOLUTION COMPRISING DOPAMINE InBrain Pharma (FR) 2025-07-23 EP disclosed
CN-120064414-A Preparation method and application of streptomycin electrochemical bionic imprinting aptamer sensor 河南科技大学 2025-05-30 CN disclosed
EP-1178994-A1 IMPROVED PROCESS FOR PHOSPHORYLATION AND COMPOUNDS PRODUCED BY THIS PROCESS Swig Pty. Ltd. (AU) 2002-02-13 EP disclosed
WO-2000069865-A1 IMPROVED PROCESS FOR PHOSPHORYLATION AND COMPOUNDS PRODUCED BY THIS PROCESS SWIG PTY LTD (AU) 2000-11-23 WO disclosed
EP-0167204-B1 METHOD FOR IMPROVING THE ABSORPTION AND EFFECTIVENESS OF A CATECHOLAMINE COMPOUND SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) 1989-09-27 EP disclosed
US-4673671-A CONVERSION TO MONO O-PHOSPHATE ESTER SIMES SOCIETA ITALIANA MEDICINALI E SINTETICI S.P.A. (IT) 1987-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091004-A1 PHARMACEUTICAL INJECTABLE SOLUTION COMPRISING DOPAMINE PARK7, SNCA, SLC6A3 KDM4E 3224/4885MAPT 578/4885MAPK1 309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.